The migration of venture capital from biopharma companies stepped up during the first three months of 2012, despite recent signs of life in the IPO market. The dollar value of VC deals fell 18% during the first quarter, while the number of deals was relatively flat. Just $780 million was invested in a total 99 biopharma companies during Q1 ’12, compared with $949 million in 97 deals during the first quarter of 2011. The report also showed a sharp year-over-year drop in first-sequence investment activity, as biopharma investors seek safer bets on established companies. There were 10 Series A deals totaling $93.2 million in Q1’12 compared to $134.3 million in 30 deals during last year’s first quarter. What are your predictions for Q2 2012?

Poll Question:
How optimistic are you that the climate for biopharma funding will improve during the rest of 2012?



Not Very


Previous articleJudge Sets May 10 Court Hearing for Icahn’s Proxy War with Amylin
Next articleFDA Clears Leica’s Her2 Immunohistochemical Assay on Bond-Max Instrument